The observation that a small molecule inhibitor of CK1 can act like the MDM2 binding molecule Nutlin to stabilize p53 and induce cell death, also suggests that CK1 forms an attractive target for anti-cancer therapeutics. This evidence concerns the gene MDM2 and cancer.